Background
Methods
Cell lines and reagents
Patient and tissue sampling
Statistical and bioinformatic analyses
Systemic HGF measurement
High-throughput screening (HTS)
Analysis of conditioned medium (CM) and plasma
Western blot
Dual-luciferase reporter assay
Migration
Animal studies
Results
Identification of miRNAs regulating fibroblast pro-tumorigenic potential
Stimulatory miRNAs | |||||
---|---|---|---|---|---|
#1 | #2 | #3 | #4 | #5 | #6 |
hsa-miR-302b (1.221) | hsa-miR-519d (1.307) | hsa-miR-519c-3p (1.305) | hsa-miR-199a-5p (1.214) | hsa-miR-146b-5p (1.261) | hsa-miR-520 h (1.191) |
hsa-miR-302c (1.374) | hsa-miR-106a (1.238) | hsa-miR-519a (1.308) | hsa-miR-199b-5p (1.225) | hsa-miR-146a (1.266) | hsa-miR-520 g (1.257) |
hsa-miR-302d (1.182) | hsa-miR-106b (1.288) | hsa-miR-519b-3p (1.291) | |||
hsa-miR-302a (1.250) | hsa-miR-20a (1.317) | ||||
hsa-miR-520e (1.219) | hsa-miR-93 (1.384) | ||||
hsa-miR-520b (1.215) | hsa-miR-20b (1.285) | ||||
hsa-miR-520c-3p (1.274) | hsa-miR-17 (1.246) | ||||
hsa-miR-372 (1.242) | |||||
hsa-miR-520d-3p (1.278) | |||||
hsa-miR-373 (1.188) |
Inhibitory miRNAs | ||||
---|---|---|---|---|
#1 | #2 | #3 | #4 | #5 |
hsa-miR-16 (0.729) | hsa-miR-28-5p (0.730) | hsa-miR-193a-3p (0.797) | hsa-miR-429 (0.689) | hsa-miR-620 (0.795) |
hsa-miR-497 (0.783) | hsa-miR-708 (0.681) | hsa-miR-193b (0.743) | hsa-miR-200b (0.754) | hsa-miR-1270 (0.797) |
hsa-miR-15b (0.787) | hsa-miR-200c (0.797) |
Smoking correlates with reduced levels of miR-16 in lung fibroblasts
Subgroup | No. of subjects | miR16 levelsa | |||||
---|---|---|---|---|---|---|---|
All | p value | CAF | p value | NF | p value | ||
Sex | |||||||
Male | 19 | 925 [441–2120] | 0.746 | 925 [487–1961] | 0.570 | 1180 [312–2109] | 0.855 |
Female | 7 | 1330 [966–1641] | 1314 [1012–2427] | 1347 [700–1494] | |||
Age | |||||||
< 70 | 15 | 1227 [384–1979] | 0.567 | 1307 [649–2069] | 0.750 | 1120 [252–1774] | 0.470 |
> 70 | 11 | 1105 [528–2120] | 919 [531–2095] | 1519 [606–1987] | |||
Histology | |||||||
Adenocarcinoma | 19 | 1112 [475–1519] | 0.488 | 1105 [733–1466] | 0.960 | 1120 [290–1519] | 0.147 |
Others | 7 | 2078 [493–2475] | 1307 [487–2966] | 2216 [916–2442] | |||
Stage | |||||||
I–II | 9 | 1105 [528–1520] | 0.566 | 800 [486–1224] | 0.520 | 1433 [762–1537] | 0.950 |
III–IV | 17 | 1227 [384–2295] | 1307 [733–2456] | 1120 [281–2120] | |||
Grade | |||||||
G2 | 4 | 1217 [916–1479]] | 0.946 | 1390 [1261–2230] | 0.628 | 734 [277–1219] | 0.490 |
G3 | 16 | 922 [452–1658] | 922 [553–2003] | 1094 [286–1572] | |||
Smoking | |||||||
Current | 12 | 860 [310–1437] | 0.215 | 1074 [722–2584] | 0.980 | 324 [223–972] | 0.006 |
Formerb/Never | 14 | 1470 [733–2120] | 1126 [517–1590] | 1589 [1494–2237] | |||
COPD (GOLD) | |||||||
0 | 15 | 1553 [826–2467] | 0.048 | 1307 [616–2711] | 0.456 | 2078 [1494–2412] | 0.004 |
1–2 | 10 | 800 [324–1233] | 860 [508–1331] | 349 [281–1120] |